On Friday, Wells Fargo & Co (NYSE:WFC)’s shares declined -2.14% to $51.31.
Wells Fargo Real Estate Investment Corporation declared that its board of directors has declared a quarterly dividend on its 6.375% cumulative perpetual preferred stock, Series A. The dividend is equal to $0.3984375 per share of Series A preferred stock.
The dividend is payable on Sept. 30, 2015, to holders of record as of the close of business on Sept. 15, 2015. Wells Fargo Real Estate Investment Corporation is an indirect partner of Wells Fargo & Company and is qualified as a real estate investment trust for federal income tax purposes.
Wells Fargo & Company provides retail, commercial, and corporate banking services to individuals, businesses, and institutions. Its Community Banking segment offers checking, savings, market rate, individual retirement, and health savings accounts, in addition to time deposits and remittances; and lines of credit, auto floor plan lines, equity lines and loans, equipment and transportation loans, education and residential mortgage loans, and debit and credit cards.
Citigroup Inc (NYSE:C)’s shares dropped -2.32% to $50.58.
Citigroup Inc. (the “Company”) (NYSE:C) declares that it is inviting eligible holders (the “Noteholders”) of its £500,000,000 4.5% Fixed Rate Subordinated Notes due 2031 (ISIN:XS0245936496) (the “Sterling Notes”), €1,250,000,000 4.25% Fixed Rate / Floating Rate Callable Subordinated Notes due 2030 (ISIN:XS0213026197) (the “Euro 2030 Notes”) or €1,500,000,000 4.375% Fixed Rate Notes due 2017 (ISIN:XS0284710257) (the “Euro 2017 Notes”, together with the Euro 2030 Notes, the “Euro Notes” and together with the Sterling Notes and the Euro 2030 Notes, the “Notes” and each a “Series”) to tender their Notes for purchase by the Company for cash (each such invitation, an “Offer”, and together, the “Offers”).
The Offers are made on the terms and subject to the conditions contained in the tender offer memorandum dated 2 September 2015 (the “Tender Offer Memorandum”, as may be amended from time to time) prepared by the Company in connection with the Offers, and are subject to the offer and distribution restrictions set out below and as more fully described in the Tender Offer Memorandum. Capitalised terms used but not otherwise defined in this declarement shall have the meanings given to them in the Tender Offer Memorandum.
Citigroup Inc., a diversified financial services holding company, provides various financial products and services for consumers, corporations, governments, and institutions worldwide. The company operates through two segments, Global Consumer Banking (GCB) and Institutional Clients Group (ICG). The GCB segment offers traditional banking services to retail customers through retail banking, commercial banking, Citi-branded cards, and Citi retail services.
At the end of Friday’s trade, Pfizer Inc. (NYSE:PFE)‘s shares dipped -1.57% to $31.36.
Pfizer Inc. (PFE) declared that it has commenced offers to exchange any and all validly tendered and accepted notes of the following series issued by Hospira, Inc. (“Hospira”), our recently attained partner, for new notes to be issued by Pfizer as described in the table below. A Registration Statement on Form S-4 (the “Registration Statement”) regarding the issuance of the Pfizer Notes (as defined below) was filed with the U.S. Securities and Exchange Commission (the “SEC”) on September 3, 2015 but has not yet been declared effective.
In connection with the exchange offers, Pfizer is also soliciting consents from holders of the Hospira Notes to amend (the “Projected Amendments”) the indenture governing the Hospira Notes (the “Hospira Indenture”) and the Hospira Notes to (i) eliminate substantially all of the restrictive covenants in the Hospira Indenture, (ii) extend the cure period for certain events of default, (iii) change the delivery date of the annual compliance certificate and (iv) modify the change of control provisions so they will no longer apply. If the Projected Amendments are adopted, the Hospira Notes will be governed by the Hospira Indenture, as amended by the Projected Amendments, which will have less restrictive terms and afford reduced protections to the holders of those securities contrast to those terms and protections presently in the Hospira Indenture and note certificates or applicable to the Pfizer Notes. In order for the Projected Amendments to the Hospira Indenture to be adopted with respect to a series of Hospira Notes, holders of not less than a majority in aggregate principal amount of the outstanding Hospira Notes of such series must consent to them, and those consents must be received preceding to the Expiration Date for the exchange offer regarding such series.
The exchange offers and consent solicitations for each series of the Hospira Notes (together, the “Exchange Offers”) will expire at 11:59 p.m., New York City time, on October 1, 2015, unless extended (the “Expiration Date”).
Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells healthcare products worldwide. The company operates through Global Innovative Pharmaceutical (GIP); Global Vaccines, Oncology and Consumer Healthcare (VOC); and Global Established Pharmaceutical (GEP) segments. The GIP segment develops, registers, and commercializes medicines for various therapeutic areas, counting inflammation, cardiovascular/metabolic, neuroscience and pain, rare diseases, and women’s/men’s health. The VOC segment develops and commercializes vaccines, in addition to products for oncology.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
